MENU

Clinical Trials & Research

The pediatric rheumatology team at Arkansas Children’s is actively involved in research to find the best treatments for pediatric arthritis and other autoimmune inflammatory conditions. Our doctors, nurses, physical therapists and other staff take part in local, national and global investigations of new and existing treatments. This means your child has access to the most advanced care available, including the opportunity to participate in clinical trials when appropriate.

Industry-Sponsored Studies

Use of Humira in children with juvenile idiopathic arthritis. A long-term, multi-center, longitudinal post-marketing, observational registry of Humira (Adalimumab) in children with active juvenile idiopathic arthritis (JIA): Sponsored by AbbVie (formerly Abbott Laboratories).

Safety and effectiveness of Certolizumab pegol in children with polyarticular juvenile idiopathic arthritis. A multicenter, open-label study to assess the pharmacokinetics, safety and efficacy of Certolizumab pegol in children and adolescents with active polyarticular-course of JIA. Sponsored by UCB Biosciences, Inc.

Use of Abatacept in children with juvenile idiopathic arthritis. An observational registry of Abatacept in patients with juvenile idiopathic arthritis. Sponsored by Bristol-Myers Squibb.

Study of Abatacept in children with active polyarticulare juvenile idiopathic arthritis. A Phase 3, multi-center, open-label study to evaluate pharmacokinetics, efficacy and safety of Abatacept administered subcutaneously in children and adolescents with active polyarticular juvenile idiopathic arthritis. Sponsored by Bristol-Myers Squibb.

Study of Tofacitinib for children with polyarticulare juvenile idiopathic arthritis. [Link to: https://clinicaltrials.gov/ct2/show/NCT02592434?term=Tofacitinib&cond=Juvenile+Idiopathic+Arthritis&rank=2] Efficacy, safety and tolerability of Tofacitinib for treatment of Poly JIA in children and adolescent subjects. Sponsored by Pfizer.

Investigator-Initiated Studies

These research studies were started by faculty members and doctors at Arkansas Children’s. 

  • Retrospective study on juvenile dermatomyositis (JDM) patients and risk of infections with biological medications. Approved in Sept 2016.
  • Examination of the immunological profile of Sjogren’s Syndrome patients. This is a collaborative study with the University of Florida at Gainesville. Approved in August 2016. Recruiting patients.